TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Robert W. Baird in a research report issued to clients and investors on Thursday. They presently have a $140.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $155.00. Robert W. Baird’s price objective would indicate a potential upside of 20.50% from the stock’s previous close.

A number of other equities research analysts have also issued reports on TSRO. Janney Montgomery Scott set a $139.00 price target on TESARO and gave the stock a “hold” rating in a research note on Saturday, June 10th. Cowen and Company set a $145.00 price target on TESARO and gave the stock a “hold” rating in a research note on Saturday, June 10th. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target on shares of TESARO in a research note on Thursday. FBR & Co cut their price target on TESARO from $200.00 to $195.00 and set a “mkt perform” rating for the company in a research note on Monday, June 5th. Finally, Cann reiterated a “buy” rating and issued a $199.00 price target on shares of TESARO in a research note on Monday, June 5th. One analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. TESARO currently has an average rating of “Buy” and an average target price of $176.35.

TESARO (TSRO) opened at 116.18 on Thursday. The stock’s market capitalization is $6.26 billion. The stock has a 50 day moving average price of $132.43 and a 200 day moving average price of $149.67. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the consensus estimate of ($2.52) by $0.30. The company had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative return on equity of 97.17% and a negative net margin of 1,301.19%. The company’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.28) earnings per share. On average, equities research analysts forecast that TESARO will post ($8.56) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/tesaro-inc-tsro-receives-neutral-rating-from-robert-w-baird.html.

In other TESARO news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at $748,155.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 40.50% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas increased its stake in shares of TESARO by 2.1% in the first quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 60 shares during the last quarter. Profund Advisors LLC increased its stake in shares of TESARO by 3.8% in the first quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 93 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of TESARO by 0.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock valued at $2,576,000 after buying an additional 150 shares during the last quarter. Aperio Group LLC increased its stake in shares of TESARO by 4.5% in the second quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 156 shares during the last quarter. Finally, Stephens Inc. AR increased its stake in shares of TESARO by 11.0% in the first quarter. Stephens Inc. AR now owns 1,759 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 175 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.